Versigent (NYSE:VGNT) Raised to Strong-Buy at UBS Group

Versigent (NYSE:VGNT) was upgraded by research analysts at UBS Group to a “strong-buy” rating in a research report issued to clients and investors on Tuesday, MarketBeat reports.

Other equities analysts have also recently issued research reports about the company. Wells Fargo & Company assumed coverage on Versigent in a report on Monday, April 6th. They set an “overweight” rating and a $35.00 price objective for the company. Fox Advisors upgraded Versigent to a “strong-buy” rating in a report on Tuesday, April 7th. TD Cowen assumed coverage on Versigent in a report on Tuesday. They set a “buy” rating and a $47.00 price objective for the company. Finally, Royal Bank Of Canada assumed coverage on Versigent in a report on Tuesday, March 31st. They set a “sector perform” rating and a $28.00 price objective for the company. Three equities research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $38.25.

Versigent Stock Up 8.1%

VGNT opened at $32.98 on Tuesday. Versigent has a 52-week low of $26.34 and a 52-week high of $34.99.